These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A new series of photoactivatable and iodinatable linear vasopressin antagonists. Carnazzi E; Aumelas A; Barberis C; Guillon G; Seyer R J Med Chem; 1994 Jun; 37(12):1841-9. PubMed ID: 8021923 [TBL] [Abstract][Full Text] [Related]
3. Characteristics of selenazolidine prodrugs of selenocysteine: toxicity, selenium levels, and glutathione peroxidase induction in A/J mice. Li L; Xie Y; El-Sayed WM; Szakacs JG; Roberts JC Life Sci; 2004 Jun; 75(4):447-59. PubMed ID: 15147831 [TBL] [Abstract][Full Text] [Related]
4. Selenazolidines as novel organoselenium delivery agents. Xie Y; Short MD; Cassidy PB; Roberts JC Bioorg Med Chem Lett; 2001 Nov; 11(22):2911-5. PubMed ID: 11677125 [TBL] [Abstract][Full Text] [Related]
5. Synthetic study on selenocystine-containing peptides. Koide T; Itoh H; Otaka A; Yasui H; Kuroda M; Esaki N; Soda K; Fujii N Chem Pharm Bull (Tokyo); 1993 Mar; 41(3):502-6. PubMed ID: 8477500 [TBL] [Abstract][Full Text] [Related]
6. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin. Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985 [TBL] [Abstract][Full Text] [Related]
7. Aza-amino acid scanning of secondary structure suited for solid-phase peptide synthesis with fmoc chemistry and aza-amino acids with heteroatomic side chains. Boeglin D; Lubell WD J Comb Chem; 2005; 7(6):864-78. PubMed ID: 16283795 [TBL] [Abstract][Full Text] [Related]
8. A convenient incorporation of conformationally constrained 5,5-dimethylproline into the ribonuclease A 89-124 sequence by condensation of synthetic peptide fragments. Cerovský V; Welker E; Scheraga HA J Pept Res; 2003 Mar; 61(3):140-51. PubMed ID: 12558949 [TBL] [Abstract][Full Text] [Related]
9. Copper-Mediated Selenazolidine Deprotection Enables One-Pot Chemical Synthesis of Challenging Proteins. Zhao Z; Metanis N Angew Chem Int Ed Engl; 2019 Oct; 58(41):14610-14614. PubMed ID: 31408267 [TBL] [Abstract][Full Text] [Related]
10. Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications. Durroux T; Peter M; Turcatti G; Chollet A; Balestre MN; Barberis C; Seyer R J Med Chem; 1999 Apr; 42(7):1312-9. PubMed ID: 10197974 [TBL] [Abstract][Full Text] [Related]
11. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136 [TBL] [Abstract][Full Text] [Related]
12. Characteristics of selenazolidine prodrugs of selenocysteine: toxicity and glutathione peroxidase induction in V79 cells. Short MD; Xie Y; Li L; Cassidy PB; Roberts JC J Med Chem; 2003 Jul; 46(15):3308-13. PubMed ID: 12852761 [TBL] [Abstract][Full Text] [Related]